drugset / Trial / NCT06660173

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173

Phase 2 Active not recruiting 409 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

Timeline

Start
2024-11-07
Primary completion
2025-10-06
Completion
2026-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Maridebart Cafraglutide Unknown Subcutaneous